SEC Form 4 · accession 0000899243-16-013272
PROTEOSTASIS THERAPEUTICS, INC. · PTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.00 | Feb 10, 2016 | A | 45,760 | A | — | Feb 10, 2026 | Common Stock | 45,760 | 45,760 | D |
Explanation of responses
- F1These securities shall vest and become exercisable in equal quarterly installments starting on February 10, 2016 until the option is fully vested and exercisable on February 10, 2019, subject to continued service.
Remarks
The Reporting Person is an employee of an affiliate of Perrigo Company plc ("Perrigo"), the indirect parent of Elan Science One Ltd. Perrigo may be deemed to beneficially own the 45,760 options granted to Mr. Walshe in his capacity as a director of the Company. Mr. Walshe has an understanding with Perrigo pursuant to which he holds such securities for the benefit of Perrigo. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.